External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home EAN 2022
Roche and Genentech at

EAN 2022

June 25 - June 28
Vienna, Austria / Virtual (Hybrid)
ean.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
01:30 PM
Duration 5mins Screen B3, Poster area in the Exhibition Hall
Disease Activity During Pregnancy and Postpartum in Women with Relapsing-Onset MS Receiving Ocrelizumab▼ in a Real-World Cohort
Yeh W, Van der Walt A, Kermode A, Kalincik T, Alroughani R, Lechner-Scott J, Boz C, Butler E, Buzzard K, Skibina O, Macdonell R, Willekens B, Prevost J, Terzi M, Liu C, Muros E, Pasquarelli N, Butzkueven H, Jokubaitis VG,on behalf of the MS Base Study Group
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:05 PM
Duration 5mins Hall B1
FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam▼ in Type 1 spinal ​muscular atrophy
Nicolas Deconinck, Giovanni Baranello, Odile Boespflug-Tanguy, John W Day, Andrea Klein, Riccardo Masson, Maria Mazurkiewicz-Beldzinska, Eugenio Mercuri, Kristy Rose, Laurent Servais, Dmitry Vlodavets, Hui Xiong, Edmar Zanoteli, Muna El-Khairi, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Angela Dodman, Eleni Gaki, Basil T Darras, on behalf of the FIREFISH Working Group
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 5mins Hall B1
SUNFISH: 3-year efficacy and safety of risdiplam▼ in Types 2 and 3 spinal muscular atrophy
Nathalie Goemans, John W Day, Nicolas Deconinck, Janbernd Kirschner, Elena S Mazzone, Andres Nacimento, Maryam Oskoui, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Odile Boespflug-Tanguy, Anna Kostera-Pruszczyk, Laurent Servais, Jessica Braid, Marianne Gerber, Ksenija Gorni, Carmen Martin, Renata S Scalco, Wai Yin Yeung, Eugenio Mercuri, on behalf of the SUNFISH Working Group
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:15 PM
Duration 5mins Vienna, Austria / Virtual (Hybrid)
Can we shift the MS curve by optimising early treatment?
Gavin Giovannoni, Matilde Inglese
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 PM
Duration 15mins Room Oslo
Efficacy and Safety of Ocrelizumab▼ in a Treatment-Naive, Early RMS Population: Data over 7 Years from the OPERA OLE Trials
Cerqueira J, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson O, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel C, Overell J, Havrdova EK
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.